Revealing the potential:
Outcomes from the iDAScore® RCT

iDAScore vs. manual morphology-based embryo selection in IVF: a randomised, double blind, non-inferiority trial

Streamlining workflow efficiency

10 times faster

evaluation with iDAScore

Similar clinical pregnancy and live birth rates as morphological EmbryoScope evaluation.

World-first randomised controlled trial (RCT) of a deep-learning AI embryo evaluation tool in IVF.

Clinics **14**

Patients **1066**

Reference: Illingworth et. al (2024), Nature Medicine.

Reflections from the authors

Together with the other clinic collaborators we're very proud to be the first in the world to carry out a randomised trial to evaluate the embryo selection ability of a deep-learning AI compared to an embryologist manually assessing them, based on physical appearance.

There is no doubt this study has huge significance, as we have witnessed first-hand at our clinics how it has improved the way we work.

Dr Peter Illingworth, Virtus Health

Our world-first trial demonstrates that blastocyst selection using deep-learning AI can not only attain similar pregnancy rates to using the Gardner grade, but it dramatically reduces the time associated with the process.

Prof David Gardner, Virtus Health

This not only benefits patients by standardising embryo selection and potentially shortening the time to achieve a pregnancy but also optimises the use of resources in IVF clinics.

Dr Christos Venetis,
IVF Australia, Virtus Health

By integrating AI with time-lapse technology, this sets a new standard for consistency and efficiency in embryo selection.

Prof Scott Nelson,
University of Glasgow, UK

These findings signify a pivotal moment in our field, as AI-powered embryo selection paired with time-lapse incubation shows its potential to achieve success rates on par with conventional methods, while notably reducing the time required for this critical task.

Dr Aishling Ahlström, Livio, Sweden

This study shows that deep-learning AI can be used to optimise clinical resources by saving time spent on evaluating embryos without compromising clinical outcomes. It is an exciting time for innovation within the field of IVF, which is exemplified by the fact that the version of iDAScore used in the study has already been improved.

Jorgen Berntsen, Data Science Manager, Vitrolife

Find out more about iDAScore and our EmbryoScope Time-lapse systems:
www.vitrolife.com/products/time-lapse-systems/embryo-decision-support-tools

Vitrolife
PART OF VITROLIFE GROUP

Vitrolife • Box 9080 • SE-400 92 Gothenburg • Sweden • Tel +46 31 721 80 00 • order@vitrolife.com • www.vitrolife.com

Reference: Illingworth et. al (2024), Nature Medicine.

iDAScore is not FDA 510(k) cleared and is not available for sale in the United States of America.